{"id":81910,"date":"2017-06-26T10:03:14","date_gmt":"2017-06-26T10:03:14","guid":{"rendered":"http:\/\/mostafa.openonline.co.uk\/?guid=4739a582d0c86ff22083e952de0f670b"},"modified":"2017-06-26T10:03:14","modified_gmt":"2017-06-26T10:03:14","slug":"news-story-cma-applies-discretion-not-to-refer-ibamallinckrodt-merger","status":"publish","type":"post","link":"https:\/\/mostafa.openonline.co.uk\/?p=81910","title":{"rendered":"News story: CMA applies discretion not to refer IBA\/Mallinckrodt merger"},"content":{"rendered":"<div class=\"govspeak\">\n<p>The companies both supply single photon emission computed tomography (<abbr title=\"single photon emission computed tomography\">SPECT<\/abbr>) radiopharmaceuticals in the UK. These are used to diagnose disease in many different tissues and organs including bones, the brain, heart, kidneys, liver, and lungs.<\/p>\n<p>The Competition and Markets Authority (<abbr title=\"Competition and Markets Authority\">CMA<\/abbr>) has found that in one category of <abbr title=\"single photon emission computed tomography\">SPECT<\/abbr> products supplied by the companies the merger will reduce the number of suppliers from 3 to 2 and this could substantially lessen competition. However, the size of the relevant market is below \u00a35 million and the <abbr title=\"Competition and Markets Authority\">CMA<\/abbr> has not found reasons to warrant an in-depth phase 2 investigation. Therefore, the <abbr title=\"Competition and Markets Authority\">CMA<\/abbr> has decided to apply its statutory discretion not to refer this case.<\/p>\n<p>This is the first case in which the <abbr title=\"Competition and Markets Authority\">CMA<\/abbr> has exercised its discretion not to make a reference for this reason since publishing <a href=\"https:\/\/www.gov.uk\/government\/news\/cma-confirms-changes-to-merger-investigations-in-smaller-markets\">revised guidance on 16 June<\/a>.<\/p>\n<p>For more information, please see the <a href=\"https:\/\/www.gov.uk\/cma-cases\/glo-dutch-bidco-mallinckrodt-netherlands-and-mallinckrodt-nuclear-medicine-merger-inquiry\">case page<\/a>.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The CMA is not referring the merger between IBA and Mallinckrodt\u2019s global nuclear imaging business for an in-depth investigation.<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"_links":{"self":[{"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=\/wp\/v2\/posts\/81910"}],"collection":[{"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=81910"}],"version-history":[{"count":0,"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=\/wp\/v2\/posts\/81910\/revisions"}],"wp:attachment":[{"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=81910"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=81910"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=81910"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}